Viscous/swallowed budesonide (DrugBank: Budesonide)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
98 | Eosinophilic gastrointestinal disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00961233 (ClinicalTrials.gov) | October 2009 | 14/8/2009 | Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE) | Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis. | Eosinophilic Esophagitis | Drug: inhaled/swallowed budesonide;Drug: viscous/swallowed budesonide | University of North Carolina, Chapel Hill | AstraZeneca | Completed | 18 Years | N/A | All | 25 | N/A | United States |